HR Execs on the Move


 
PetMeds® is America`s Largest Pet Pharmacy, a publicly traded company (NASDAQ: PETS). We deliver prescription and non-prescription pet meds along with health and nutritional supplements for dogs, cats and horses at substantial savings directly to you. We serve millions of satisfied customers nationwide from one location.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.petmeds.com
  • 420 South Congress Avenue Suite 100
    Delray Beach, FL USA 33445
  • Phone: 800.738.6337

Executives

Name Title Contact Details
Jacqueline Smith
Vice President of People Profile
Dan Pingree
Chief Marketing Officer Profile

Similar Companies

Advanced Pharmacy Concepts

Advanced Pharmacy Concepts is a North Kingstown, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChristieCampusHealth

CONNECT@College from Christie Campus Health helps colleges provide behavioral and mental health support for students, and logistical support for campus healthcare providers.

Vishnu Chemicals Limited

Vishnu Chemicals Limited is a Eatontown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BN ImmunoTherapeutics

BN ImmunoTherapeutics is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.